Roberto Bianchini

A 20-year experience with mitral valve repair with artificial chordae in 608 patients

OBJECTIVE Mitral valve repair with artificial chordae for degenerative mitral regurgitation is widely adopted. We evaluated long-term results of mitral repair with expanded polytetrafluoroethylene sutures (GORE-TEX CV-5; W. L. Gore & Associates, Inc, Flagstaff, Ariz). METHODS Between November 1986 and November 2006, 608 consecutive patients underwent mitral repair with artificial neochordae. Mean age was 55 +/- 11 years (15-85 years); 433 (71.2%) were male. Valve disease was purely degenerative in 555 patients (91.3%). Prolapse of anterior, posterior, or both leaflets was present in 47 (7.7%), 308 (50.7%), and 253 (41.6%), respectively. Atrial fibrillation was associated in 117 (19.2%). In 125 cases (20.5%), additional surgical procedures were performed. Follow-up was complete at a median of 5.7 years (interquartile range 2.2-9.8 years, range 0-19.4 years). RESULTS In-hospital mortality was less than 1% (6 deaths). Overall and cardiac late mortalities were 6.6% and 3.9% (34 and 24 deaths). Kaplan-Meier survival at 15 years was 84% (95% confidence interval 75%-90%). Freedoms from endocarditis, thromboembolic events, reoperation, and recurrent mitral regurgitation at 15 years were 97% (95% confidence interval 93%-99%), 92% (87%-95%), 92% (88%-95%), and 85% (78%-91%), respectively. Sinus rhythm was restored in 75% (33 patients) after surgical atrial fibrillation correction. Calcification of GORE-TEX neochordae was never reported. CONCLUSION Mitral valve repair with GORE-TEX artificial chordae is effective, safe, and associated with low operative mortality and low rates of valve-related complications at long-term follow-up. Artificial chordae showed excellent biologic adaptation, retaining flexibility and tension with time.

Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery

OBJECTIVES Coronary artery bypass graft surgery may result in perioperative myocardial injury during cardioplegic arrest. Angiotensin-converting enzyme (ACE) inhibitors protect the myocardium from ischemia in several clinical conditions, but no previous study has attempted to evaluate the impact of preoperative ACE inhibitor therapy on myocardial protection in patients undergoing coronary artery bypass graft surgery. METHODS A propensity score-based analysis of 481 patients undergoing isolated on-pump coronary artery bypass graft surgery was carried out, among which 245 patients received preoperative ACE inhibitors and 236 patients did not. Perioperative myocardial injury was assessed by ischemia marker cardiac troponin I (cTnI). RESULTS Preoperative cTnI concentration was similar for patients receiving ACE inhibitors and those who did not [0.1 ng/ml (0.06-0.19) versus 0.1 ng/ml (0.06-0.19); P = 0.3]. Postoperative cTnI peak concentration was lower in patients receiving preoperative ACE inhibitors [1.6 ng/ml (1.05-3.4) versus 2.4 ng/ml (1.13-6.10); P = 0.0006]. After adjusting for propensity score and covariates, preoperative ACE inhibitors were found to decrease postoperative cTnI peak concentration (beta = -0.12; P = 0.004). Other independent predictors of postoperative cTnI peak concentration were female gender, emergency surgery, number of distal anastomoses and aortic cross clamp time. Overall, operative mortality rate was 16/481 (3.3%). Patients receiving preoperative ACE inhibitors had a lower rate of postoperative myocardial infarction (2.0 versus 4.2%; P = 0.25) and low cardiac output syndrome (3.6 versus 6.3%; P = 0.24). CONCLUSION ACE inhibitors prior to surgery confer added myocardial protection during surgical revascularization. Prospective, randomized clinical trials will be necessary to better define the role of ACE inhibitors in improving outcomes when they are prescribed prior to coronary artery bypass graft surgery.Objectives Coronary artery bypass graft surgery may result in perioperative myocardial injury during cardioplegic arrest. Angiotensin-converting enzyme (ACE) inhibitors protect the myocardium from ischemia in several clinical conditions, but no previous study has attempted to evaluate the impact of preoperative ACE inhibitor therapy on myocardial protection in patients undergoing coronary artery bypass graft surgery. Methods A propensity score-based analysis of 481 patients undergoing isolated on-pump coronary artery bypass graft surgery was carried out, among which 245 patients received preoperative ACE inhibitors and 236 patients did not. Perioperative myocardial injury was assessed by ischemia marker cardiac troponin I (cTnI). Results Preoperative cTnI concentration was similar for patients receiving ACE inhibitors and those who did not [0.1 ng/ml (0.06–0.19) versus 0.1 ng/ml (0.06–0.19); P = 0.3]. Postoperative cTnI peak concentration was lower in patients receiving preoperative ACE inhibitors [1.6 ng/ml (1.05–3.4) versus 2.4 ng/ml (1.13–6.10); P = 0.0006]. After adjusting for propensity score and covariates, preoperative ACE inhibitors were found to decrease postoperative cTnI peak concentration (β = −0.12; P = 0.004). Other independent predictors of postoperative cTnI peak concentration were female gender, emergency surgery, number of distal anastomoses and aortic cross clamp time. Overall, operative mortality rate was 16/481 (3.3%). Patients receiving preoperative ACE inhibitors had a lower rate of postoperative myocardial infarction (2.0 versus 4.2%; P = 0.25) and low cardiac output syndrome (3.6 versus 6.3%; P = 0.24). Conclusion ACE inhibitors prior to surgery confer added myocardial protection during surgical revascularization. Prospective, randomized clinical trials will be necessary to better define the role of ACE inhibitors in improving outcomes when they are prescribed prior to coronary artery bypass graft surgery.

Residual SYNTAX score following coronary artery bypass grafting

Objectives To quantify residual coronary artery disease measured using the SYNTAX score (SS) and its relation to outcomes after coronary artery bypass grafting (CABG). Methods We conducted a retrospective analysis on a consecutive series of 1608 patients [mean age 68 years, standard deviation (SD): 7, F:M, 242:1366] undergoing first-time isolated CABG from 2004 to 2015. The baseline SS was retrospectively determined from preoperative angiograms, and the residual SS (rSS) was measured during assessment of the actual operative report for each patient after CABG. Patients were then stratified according to tercile cut points of low (rSS low 0-11, N  = 537), intermediate (rSS mid  >11-18.5, N  = 539) and high residual SS (rSS high  >18.5, N  = 532). The Cox regression model was used to investigate the impact of rSS on major adverse cardiac and cerebrovascular events (MACCE) at 1 year. Results The mean preoperative SS was 26.6 (SD: 9.4) (range 10.1-53), and the residual SS after CABG was 15.3 (SD: 8.4) (range 0-34) ( P  <   0.001 versus preoperative). At 1 year, cumulative incidence of MACCE in the low rSS was 1.5% ( N  = 8/537), 4.5% ( N  = 24/539) in the intermediate and 8.8% ( N  = 47/532) in the high rSS group. Kaplan-Meier analysis showed a statistically significant difference of MACCE-free survival between the three groups (log-rank test, P  <   0.001). The estimated MACCE-free survival rate at 1 year was 98.1% [standard error (SE): 1.6] for the rSS low , 95.5% (SE: 1.9) for the rSS mid , and 90.5% (SE: 1.3) for the rSS high group, respectively. After multivariable adjustment, the rSS high group was independently associated with a higher incidence of MACCE at 1 year (hazard ratio 1.92, 95% confidence interval 1.21-3.23) compared to the rSS low group. Conclusions These unanticipated findings suggest that a residual SS may be a useful tool for risk stratification of patients undergoing isolated first-time CABG. Our study may set the stage for further investigations addressing this important clinical question.

Miniaturized versus conventional cardiopulmonary bypass in patients undergoing coronary artery bypass surgery: impact on lymphocyte depletion and sternal wound healing.

To reduce deleterious effects of C-CPB novel concepts have been developed based on miniaturized cardiopulmonary bypass (Mini-CPB) with closed circuits, low priming volumes and optimized perfusion system. In CABG surgery, it has previously shown that the use of Mini-CPB can reduce systemic inflammation compared to C-CPB [25] and so attenuate the pathologic effects of C-CPB.

Blackish Pigmentation of the Aorta in Patient with Alkaptonuria and Heyde's Syndrome.

Alkaptonuria is an autosomal recessive trait resulting in an error of aromatic amino acids metabolism. Heydes syndrome is a condition clustering together aortic valve stenosis and gastrointestinal bleeding from colonic angiodysplasia. At present, there is no report describing the association of the latter two syndromes in the same patient. Here we present the case of a patient with severe aortic stenosis, alkaptonuria, and Heydes syndrome. The patient underwent aortic valve replacement by means of a valvular bioprosthesis and the histological examination of the aortic cusps revealed calcific degeneration. This was associated with stromal degeneration characterized by extra-cellular deposition of granular, brownish-pigmented material along with macrophages and multiple foci of calfication showing the same brownish pigmentation. This configuration represents the typical pattern of homogentisic acid accumulation known as ochronosis. The postoperative course was uneventful and the echocardiographic follow-up at 6 months postoperatively showed good-functioning of the aortic valve bioprosthesis.